An international study to test drugs that may prevent or delay Alzheimer’s disease is adding a third drug arm. Participants who receive the drug or placebo will be monitored for at least four years for signs of the disease.
Ongoing international research led by Washington University investigators is changing the Alzheimer’s disease landscape from hopeless to hopeful.
Washington University School of Medicine in St. Louis has received a $4.3 million award from the Alzheimer’s Association to expand a major international clinical trial evaluating whether drugs can prevent Alzheimer’s disease in patients genetically predisposed to develop the devastating disease at a young age.